Zacks Research Equities Analysts Increase Earnings Estimates for GSK plc (NYSE:GSK)

GSK plc (NYSE:GSK) – Stock analysts at Zacks Research lifted their Q4 2024 EPS estimates for shares of GSK in a report issued on Tuesday, June 25th. Zacks Research analyst E. Bagri now expects that the pharmaceutical company will post earnings of $0.84 per share for the quarter, up from their prior estimate of $0.83. The consensus estimate for GSK’s current full-year earnings is $4.11 per share. Zacks Research also issued estimates for GSK’s Q2 2025 earnings at $1.00 EPS.

GSK (NYSE:GSK) last issued its earnings results on Wednesday, May 1st. The pharmaceutical company reported $1.09 EPS for the quarter, topping analysts’ consensus estimates of $0.94 by $0.15. GSK had a net margin of 14.62% and a return on equity of 51.54%. The company had revenue of $9.34 billion for the quarter, compared to analysts’ expectations of $8.98 billion.

A number of other brokerages have also recently commented on GSK. Berenberg Bank raised GSK to a “strong-buy” rating in a research note on Thursday, June 20th. The Goldman Sachs Group began coverage on shares of GSK in a research note on Thursday, May 30th. They issued a “neutral” rating and a $47.00 target price on the stock. Guggenheim raised shares of GSK from a “neutral” rating to a “buy” rating in a research report on Monday, March 4th. Finally, Citigroup raised shares of GSK to a “strong-buy” rating in a report on Monday, June 24th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, two have given a buy rating and three have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, GSK currently has an average rating of “Moderate Buy” and an average target price of $47.00.

GSK Stock Down 0.4 %

GSK opened at $38.50 on Friday. The company has a market cap of $79.79 billion, a P/E ratio of 13.95, a P/E/G ratio of 1.17 and a beta of 0.66. GSK has a 12 month low of $33.67 and a 12 month high of $45.92. The business’s 50-day moving average price is $42.51 and its 200-day moving average price is $41.20. The company has a current ratio of 0.87, a quick ratio of 0.58 and a debt-to-equity ratio of 1.15.

GSK Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, July 11th. Investors of record on Friday, May 17th will be paid a $0.3762 dividend. This is a positive change from GSK’s previous quarterly dividend of $0.36. The ex-dividend date is Thursday, May 16th. This represents a $1.50 dividend on an annualized basis and a yield of 3.91%. GSK’s dividend payout ratio (DPR) is presently 53.26%.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Versant Capital Management Inc increased its position in shares of GSK by 2,816.7% during the fourth quarter. Versant Capital Management Inc now owns 700 shares of the pharmaceutical company’s stock valued at $26,000 after buying an additional 676 shares during the period. Register Financial Advisors LLC bought a new position in shares of GSK in the 1st quarter worth approximately $31,000. BKM Wealth Management LLC purchased a new position in shares of GSK in the 4th quarter valued at approximately $32,000. Richardson Financial Services Inc. bought a new stake in shares of GSK during the fourth quarter valued at approximately $40,000. Finally, Jones Financial Companies Lllp grew its stake in GSK by 62.2% in the third quarter. Jones Financial Companies Lllp now owns 1,327 shares of the pharmaceutical company’s stock worth $48,000 after purchasing an additional 509 shares during the period. 15.74% of the stock is owned by hedge funds and other institutional investors.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.